Trial Profile
Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Salmeterol (Primary) ; Fluticasone propionate
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 07 Dec 2022 Results (n=46) assessing whether gene expression signatures obtained in asthma can be used to identify the subgroup of patients with COPD with steroid sensitivity published in the Thorax
- 09 Nov 2009 New trial record.
- 20 Oct 2009 Results were reported in the Annals of Internal Medicine.